OneSource Specialty Pharma Limited returned to profitability in the first quarter of FY26, reporting a consolidated net profit of ₹292.97 million compared to a net loss of ₹26.84 million in the corresponding period of FY25. The turnaround was driven by a 37.2% year-on-year surge in consolidated revenue from operations, which reached ₹4,490.23 million against ₹3,272.70 million in Q1FY25. This performance marks a significant operational improvement for the contract development and manufacturing organization (CDMO), as it exited a loss-making position seen in the prior year’s quarter.

The Board of Directors, chaired by Managing Director Neeraj Sharma, approved the unaudited financial results during its meeting held on July 24, 2026. The company filed the extract of its financial results with the stock exchanges pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the consolidated and standalone financial results is available on the company’s website and the respective exchange portals.

Financial Performance Highlights

The company’s financial metrics for Q1FY26 reflect strong top-line growth and improved bottom-line health across both consolidated and standalone structures. Standalone revenue also grew significantly, rising to ₹4,464.71 million from ₹3,210.12 million in Q1FY25.

Note: The consolidated net profit after tax for Q1FY25 was ₹26.84 million, indicating a profit rather than a loss in that specific line item, though the pre-tax figure was negative. However, another line item shows a loss of ₹(1.86) million after tax and exceptional items for the same period. The primary comparison uses the standard net profit after tax figure.

What the Numbers Show

The divergence between pre-tax and post-tax profits in the consolidated figures warrants attention. While the company reported a pre-tax loss of ₹(15.29) million in Q1FY25, it posted a post-tax profit of ₹26.84 million, suggesting significant other income or tax benefits offsetting operational losses in the prior year. In Q1FY26, both pre-tax (₹245.94 million) and post-tax (₹292.97 million) figures are positive, indicating that the current profitability is operationally driven rather than reliant on non-operating gains. The standalone segment consistently outperformed the consolidated entity in terms of net profit, with standalone PAT at ₹512.25 million, highlighting potential consolidation adjustments or subsidiary impacts reducing the group-wide bottom line.

The earnings per share (EPS) also reflected this recovery, with basic consolidated EPS rising to ₹2.18 from ₹(0.02) in the previous year. Shareholders can access the detailed financial statements via the QR code provided in the original filing or through the company’s investor relations page.

OneSource Specialty Pharma has restructured its Senior Management Personnel (SMP) with immediate effect from July 24, 2026. The company accepted the resignation of Ravi Kumar, who served as Global Head – Injectables and Head of Corporate Strategy, Portfolio & SPO. Simultaneously, Preeti Kalra was designated as an SMP, assuming the role of Head – Human Resources. These changes reflect a shift in leadership focus, replacing a strategic and operational head with a senior human resources executive, signaling a potential emphasis on organizational transformation and talent management.

The disclosures were made pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing also referenced SEBI Master Circular No. HO/49/14/14(7) 2025-CFD-POD2/I/ 3762/2026, last updated on January 30, 2026. Company Secretary and Compliance Officer Trisha A authenticated the submission on July 24, 2026.

Leadership Changes

Ravi Kumar ceased to be an SMP consequent to his resignation. He held dual responsibilities overseeing injectables operations and corporate strategy, portfolio management, and shared procurement organization (SPO). His departure marks a significant change in the company’s strategic and operational leadership structure.

Preeti Kalra was designated as an SMP effective July 24, 2026. Her appointment brings extensive cross-sector experience to the company’s senior management team.

New Appointee Profile

Preeti Kalra brings more than 25 years of experience across biopharma, global development, public services, insurance, global capability centers (GCC), and IT sectors. Her professional background includes leadership roles at Stelis Biopharma, Biocon Biologics, the Bill & Melinda Gates Foundation, Serco, and Ernst & Young.

Kalra’s expertise lies in organizational transformation, culture building, and change management. She has a proven track record of enabling business growth by building high-performing teams and strengthening leadership capabilities across multiple global regions.

Regulatory Compliance

The company enclosed Annexure 1 and Annexure 2 with the disclosure, detailing the designation of Preeti Kalra and the cessation of Ravi Kumar, respectively. Both annexures confirmed that there were no relationships between directors requiring disclosure for these specific personnel changes. The date of cessation for Ravi Kumar was listed as NA in the annexure table, though the effective date of resignation is July 24, 2026, as stated in the primary disclosure.